These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

815 related articles for article (PubMed ID: 9085733)

  • 1. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
    Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation.
    Neubauer MA; Benyunes MC; Thompson JA; Bensinger WI; Lindgren CG; Buckner CD; Fefer A
    Bone Marrow Transplant; 1994 Mar; 13(3):311-6. PubMed ID: 7911048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
    Triozzi PL; Tucker F; Benzies T; Balcerzak SP
    Bone Marrow Transplant; 1996 Jul; 18(1):47-52. PubMed ID: 8831995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of human monocyte function against Candida albicans by autologous IL-2-induced lymphokine-activated killer cells.
    Wei S; Serbousek D; McMillen S; Blanchard DK; Djeu JY
    J Immunol; 1991 Jan; 146(1):337-42. PubMed ID: 1898605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction.
    Stewart-Akers AM; Cairns JS; Tweardy DJ; McCarthy SA
    Blood; 1993 May; 81(10):2671-8. PubMed ID: 8490177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines.
    Parhar RS; Ernst P; Sheth KV; al-Sedairy ST
    Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    Klasa RJ; Silver HK; Kong S
    Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR; Parreira A; Ascensão JL
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
    Saarloos MN; Khoo NK; Lala PK
    Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of human monocyte susceptibility to lymphokine-activated killer cell lysis by granulocyte-macrophage colony-stimulating factor.
    Blanchard DK; Serbousek D; Djeu JY
    Cancer Res; 1989 Sep; 49(18):5037-43. PubMed ID: 2670200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
    Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS
    Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human GM-CSF enhances T cell-mediated cytotoxic function after ABMT for hematological malignancies.
    Richard C; Alsar MJ; Calavia J; Bello-Fernandez C; Baro J; Loyola I; Rios R; Cuadrado MA; Gonzalez-Pardo C; Iriondo A
    Bone Marrow Transplant; 1993 Jun; 11(6):473-8. PubMed ID: 8334429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-fluorouracil permits access to a primitive subpopulation of peripheral blood stem cells.
    Rice A; Barbot C; Lacombe F; Dubosc-Marchenay N; Marit G; Hau F; Boiron JM; Reiffers J
    Stem Cells; 1993 Jul; 11(4):326-35. PubMed ID: 8401256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors.
    Verma UN; Areman E; Dickerson SA; Kotula PL; Sacher R; Mazumder A
    Bone Marrow Transplant; 1995 Feb; 15(2):199-206. PubMed ID: 7773209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological characterization of CD34+ cells mobilized into peripheral blood.
    Lemoli RM; Tafuri A; Fortuna A; Catani L; Rondelli D; Ratta M; Tura S
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S47-50. PubMed ID: 9989890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
    Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
    Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.